Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
Express Scripts
Merck
McKinsey

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for INCB039110


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug INCB039110?

INCB039110 is an investigational drug.

There have been 42 clinical trials for INCB039110. The most recent clinical trial was a Phase 3 trial, which was initiated on July 19th 2017.

The most common disease conditions in clinical trials are Graft vs Host Disease, Primary Myelofibrosis, and Neoplasms. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are twenty-six US patents protecting this investigational drug and three hundred and thirty-six international patents.

Recent Clinical Trials for INCB039110
TitleSponsorPhase
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)Astex PharmaceuticalsPhase 1/Phase 2
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)Astex Pharmaceuticals, Inc.Phase 1/Phase 2
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)Incyte CorporationPhase 1/Phase 2

See all INCB039110 clinical trials

Clinical Trial Summary for INCB039110

Top disease conditions for INCB039110
Top clinical trial sponsors for INCB039110

See all INCB039110 clinical trials

US Patents for INCB039110

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INCB039110 ⤷  Sign up for a Free Trial Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign up for a Free Trial
INCB039110 ⤷  Sign up for a Free Trial Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign up for a Free Trial
INCB039110 ⤷  Sign up for a Free Trial Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INCB039110

Drugname Country Document Number Estimated Expiration Related US Patent
INCB039110 World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Sign up for a Free Trial
INCB039110 World Intellectual Property Organization (WIPO) WO2017035366 2035-08-26 ⤷  Sign up for a Free Trial
INCB039110 Australia AU2015244044 2034-04-08 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
Express Scripts
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.